Skip to main content

Table 2 Clinicopathological features of neo-adjuvant chemotherapy cases according to chemo-effect (n = 134)

From: Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients

  

pCR

non-pCR

P-value

Variables

 

n a

% b

n a

% b

 

n

 

57

 

77

  

Age (mean, range)

 

52.8

26–81

51.9

26–79

0.665

Histologyc

NST

53

93

76

99

0.084

 

Special type

4

7

1

1

 

Tumor gradec

High

16

28

24

31

0.980

 

Low/intermediate

35

61

52

68

 
 

Not evaluated

6

11

1

1

 

Ki67 LI (%) (mean, range)c

61.4

10–90

49.7

5–95

0.009

ERc

Positive

33

58

46

60

0.830

 

Negative

24

42

31

40

 

PgRc

Positive

18

32

31

40

0.302

 

Negative

39

68

46

60

 

HER2c

3+

54

95

66

86

0.091

 

2 + FISH+

3

5

11

14

 

Chemotherapyd

A + T

56

98

63

82

0.019

 

 A only

0

0

11

14

 
 

T only

1

2

2

3

 
 

Others

0

0

1e

1

 

Anti-HER2 therapyd

Tra only

38

67

45

58

0.076

 

Tra + Per

8

14

5

6

 
 

None

11

19

27

35

 
  1. pCR pathological complete response, NST no special type, LI labelling index, A anthracycline, T taxane, Tra trastuzumab, Per pertuzumab
  2. a Presented as n unless otherwise noted to be mean
  3. b Presented as % unless otherwise noted to be range
  4. c Assessed on biopsy for neo-adjuvant chemotherapy (NAC) cases
  5. d For NAC
  6. e Capecitabe was given with trastuzumab
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us